Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$1.95
-1.0%
$1.85
$1.33
$2.89
$57.51M1.75412,478 shs197,218 shs
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
$24.99
+0.3%
$9.20
$4.30
$13.66
$1.26B1.531.18 million shsN/A
MedAvail Holdings, Inc. stock logo
MDVL
MedAvail
$3.31
$1.31
$20.89
$2.91M0.76261,432 shs245,100 shs
Urogen Pharma stock logo
URGN
Urogen Pharma
$15.38
+7.2%
$10.18
$3.42
$17.27
$711.89M1.021.10 million shs1.44 million shs
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
$26.72
+0.4%
$25.75
$18.35
$35.00
$315.75M0.9336,286 shs8,455 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
+1.55%-1.01%+7.07%+28.76%-2.96%
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
-0.26%-0.10%+173.24%+173.24%+173.24%
MedAvail Holdings, Inc. stock logo
MDVL
MedAvail
0.00%0.00%0.00%0.00%0.00%
Urogen Pharma stock logo
URGN
Urogen Pharma
+2.14%+3.84%0.00%+48.29%-16.72%
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
+1.33%-3.97%+9.64%+25.64%-1.44%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
2.5371 of 5 stars
3.51.00.00.02.23.30.6
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
MedAvail Holdings, Inc. stock logo
MDVL
MedAvail
N/AN/AN/AN/AN/AN/AN/AN/A
Urogen Pharma stock logo
URGN
Urogen Pharma
4.3331 of 5 stars
4.52.00.04.51.32.50.0
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
3.8058 of 5 stars
3.52.00.03.01.52.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
3.00
Buy$21.00976.92% Upside
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
0.00
N/AN/AN/A
MedAvail Holdings, Inc. stock logo
MDVL
MedAvail
0.00
N/AN/AN/A
Urogen Pharma stock logo
URGN
Urogen Pharma
3.00
Buy$32.86113.69% Upside
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
3.00
Buy$69.50160.15% Upside

Current Analyst Ratings Breakdown

Latest FBIO, URGN, FLXN, XOMA, and MDVL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00
7/7/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
6/16/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$50.00
6/13/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetNeutral ➝ Neutral$16.00
6/13/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperform ➝ Buy$31.00
6/13/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
6/13/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Outperform ➝ Sector Outperform$23.00 ➝ $47.00
6/13/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $30.00
6/12/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
6/3/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$36.00 ➝ $10.00
5/28/2025
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$104.00
(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$57.67M1.00N/AN/A($0.06) per share-32.50
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
$85.55M14.70N/AN/A($0.34) per share-73.49
MedAvail Holdings, Inc. stock logo
MDVL
MedAvail
$43.33M0.00N/AN/A$13.01 per share0.00
Urogen Pharma stock logo
URGN
Urogen Pharma
$90.40M7.84N/AN/A($0.21) per share-73.22
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
$13.05M24.50N/AN/A$6.95 per share3.84
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
-$46M-$2.23N/AN/AN/A-71.24%-4,712.53%-27.67%8/12/2025 (Estimated)
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
-$113.71M-$2.01N/AN/AN/A-100.32%N/A-44.26%N/A
MedAvail Holdings, Inc. stock logo
MDVL
MedAvail
-$47.62M-$28.72N/AN/AN/A-192.97%-218.10%-103.45%N/A
Urogen Pharma stock logo
URGN
Urogen Pharma
-$126.87M-$3.18N/AN/AN/A-150.68%-97,487.15%-49.57%8/12/2025 (Estimated)
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
-$13.82M-$1.15N/AN/AN/A-13.04%-12.43%-4.85%8/12/2025 (Estimated)

Latest FBIO, URGN, FLXN, XOMA, and MDVL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
-$0.31N/AN/AN/A$14.53 millionN/A
8/12/2025Q2 2025
Urogen Pharma stock logo
URGN
Urogen Pharma
-$0.85N/AN/AN/A$23.06 millionN/A
8/12/2025Q2 2025
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
-$0.12N/AN/AN/A$9.39 millionN/A
5/13/2025Q1 2025
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
-$0.26$0.06+$0.32$0.06$6.75 million$15.91 million
5/12/2025Q1 2025
Urogen Pharma stock logo
URGN
Urogen Pharma
-$0.83-$0.92-$0.09-$0.92$22.71 million$20.25 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
N/AN/AN/AN/AN/A
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
N/AN/AN/AN/AN/A
MedAvail Holdings, Inc. stock logo
MDVL
MedAvail
N/AN/AN/AN/AN/A
Urogen Pharma stock logo
URGN
Urogen Pharma
N/AN/AN/AN/AN/A
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
1.74
1.72
1.55
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
N/A
4.38
4.05
MedAvail Holdings, Inc. stock logo
MDVL
MedAvail
N/AN/AN/A
Urogen Pharma stock logo
URGN
Urogen Pharma
N/A
5.65
5.47
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
1.18
5.54
5.54

Institutional Ownership

CompanyInstitutional Ownership
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
96.51%
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
90.01%
MedAvail Holdings, Inc. stock logo
MDVL
MedAvail
N/A
Urogen Pharma stock logo
URGN
Urogen Pharma
91.29%
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
95.92%

Insider Ownership

CompanyInsider Ownership
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
27.90%
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
9.13%
MedAvail Holdings, Inc. stock logo
MDVL
MedAvail
1.50%
Urogen Pharma stock logo
URGN
Urogen Pharma
5.10%
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
9.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
17029.57 million21.32 millionOptionable
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
25750.32 million45.73 millionNo Data
MedAvail Holdings, Inc. stock logo
MDVL
MedAvail
2791.61 million1.59 millionNo Data
Urogen Pharma stock logo
URGN
Urogen Pharma
20046.11 million43.76 millionOptionable
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
1011.97 million10.88 millionOptionable

Recent News About These Companies

Top biotech deals in June 2025
XOMA Royalty to Buy Turnstone Biologics
XOMA Corp - 8.375% DP PFD B declares $0.5234 dividend

New MarketBeat Followers Over Time

Media Sentiment Over Time

Fortress Biotech stock logo

Fortress Biotech NASDAQ:FBIO

$1.95 -0.02 (-1.02%)
As of 03:05 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Flexion Therapeutics stock logo

Flexion Therapeutics NASDAQ:FLXN

Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.

MedAvail stock logo

MedAvail NASDAQ:MDVL

MedAvail Holdings, Inc., a technology-enabled retail pharmacy technology and services company, develops and commercializes self-service pharmacy, mobile application, and kiosk solutions in the United States and Canada. It offers a pharmacy technology solution, including the MedAvail MedCenter, which enables on-site pharmacy in medical clinics, retail store locations, employer sites with and without onsite clinics, and other location where onsite prescription dispensing is desired, as well as establishes an audio-visual connection to a live pharmacist enabling prescription drug dispensing to occur directly to a patient with real-time supervision by a pharmacist. The company is headquartered in Phoenix, Arizona. On February 2, 2024, MedAvail Holdings, Inc along with its affiliates, filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

Urogen Pharma stock logo

Urogen Pharma NASDAQ:URGN

$15.38 +1.04 (+7.22%)
As of 03:05 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

XOMA Royalty stock logo

XOMA Royalty NASDAQ:XOMA

$26.72 +0.11 (+0.39%)
As of 03:05 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.